search

Active clinical trials for "Lymphoma, B-Cell"

Results 1401-1410 of 1412

Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients...

Diffuse Large B Cell LymphomaPeripheral T Cell Lymphoma

The purpose of this study is to evaluate the effectiveness of circulating DNA from peripheral blood for predicting the prognosis and relapse in DLBCL and PTCL patients.

Unknown status6 enrollment criteria

An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With...

B-cell Lymphoma

An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy with Tenofovir in HBsAg-positive Patients with Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED study)

Unknown status12 enrollment criteria

A Compassionate Use (CU) Program of Odronextamab

Relapsed or Refractory (R/R) Follicular Lymphoma (FL)Diffuse Large B-Cell Lymphoma (DLBCL)2 more

Provide compassionate use of odronextamab

Available0 enrollment criteria

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory...

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials. ADC Therapeutics will evaluate patients for approval into the program.

No longer available15 enrollment criteria

Axicabtagene Ciloleucel Expanded Access Study

Relapsed/Refractory Diffuse Large B Cell LymphomaRelapsed/Refractory Primary Mediastinal B Cell Lymphoma2 more

A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma. Subjects who received an infusion of KTE-X19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

Approved for marketing35 enrollment criteria

Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)...

Chronic Hepatitis C

An prospective / retrospective multicenter observational study whose objectives are to understand the interactions between hepatitis c virus and Non Hodgkin lymphomas. The characteristics , evolution and treatment of diseases will be observed from the study.

Unknown status10 enrollment criteria

Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?...

LymphomaB-Cell

The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy. Even though many randomized and non-randomized studies have been conducted, their is still no standard procedure . Recently, the use of early TEP (positron emission topography) answer, after 2 in 3 cures of chemotherapy allowed to select the poor-responder patients who remain candidate to autograft in front-line. Nevertheless, in good-responder patients, the benefits of an intensification therapy ins term of long-lasting disease control remains discussion. This institutional retrospective study aims at comparing the outcome of early metabolic responder patients who received an intensification treatment to those who received a standard chemotherapy.

Unknown status3 enrollment criteria

Secondary Prognostic Index in RefrActory Lymphoma

Diffuse Large B Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

60% of patients with diffuse large B cell lymphoma are healed after first-line treatment which whatever the age. For the remaining 40% of patients (relapses and primary refractories): 38% of patients will be cured with a 2nd line including an autologous haematopoietic cell transplantation for those under 65 years. for older patients who are not eligible for a autograft: only 70% of patients will be able to receive 2nd line treatment with rates response less than 50%. the survival rate in patients receiving 3rd line treatment or more is 15% at 2 years. Actually, no standard of chemotherapy is offered to relapsed or refractory patients after 2 therapeutic lines. Subsequent lines lead to hospitalizations for infectious complications or transfusions without clear clinical benefit with often an impacted quality of life. Palliative care is rarely offered as part of the treatment overall load.

Unknown status6 enrollment criteria

Marginal Zone Lymphoma Cohort in Korea

LymphomaB-Cell1 more

Marginal zone lymphoma is a rare of subtype of Non-Hodgkin Lymphoma. Because of its rarity, prospective clinical trial is difficult to conduct. Therefore we want to make prospective MZL patients' cohort for several observation study

Unknown status9 enrollment criteria

A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large...

Diffuse Large B Cell Lymphoma

The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.

Unknown status3 enrollment criteria
1...140141142

Need Help? Contact our team!


We'll reach out to this number within 24 hrs